Modulation of Cisplatin Sensitivity and Growth Rate of an Ovarian Carcinoma Cell Line by Bombesin and Tumor Necrosis Factor-Alpha. by Isonishi, Seiji et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
10-1-1992
Modulation of Cisplatin Sensitivity and Growth
Rate of an Ovarian Carcinoma Cell Line by
Bombesin and Tumor Necrosis Factor-Alpha.
Seiji Isonishi
Jikei University School of Medicine
Antti P. Jekunen
University of California San Diego
Doreen K. Hom
University of California San Diego
Alan Eastman
Dartmouth College
Peter S. Edelstein
University of California San Diego
See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Isonishi, Seiji; Jekunen, Antti P.; Hom, Doreen K.; Eastman, Alan; Edelstein, Peter S.; Thiebaut, Franz B.; Christen, Randolph D.; and
Howell, Stephen B., "Modulation of Cisplatin Sensitivity and Growth Rate of an Ovarian Carcinoma Cell Line by Bombesin and
Tumor Necrosis Factor-Alpha." (1992). Open Dartmouth: Faculty Open Access Articles. 3619.
https://digitalcommons.dartmouth.edu/facoa/3619
Authors
Seiji Isonishi, Antti P. Jekunen, Doreen K. Hom, Alan Eastman, Peter S. Edelstein, Franz B. Thiebaut,
Randolph D. Christen, and Stephen B. Howell
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/3619
Modulation of Cisplatin Sensitivity and Growth Rate of an Ovarian
Carcinoma Cell Line by Bombesin and Tumor Necrosis Factor-a
Seiji Isonishi,* Antti P. Jekunen,t Doreen K. Horn,t Alan Eastman,' Peter S. Edelstein,I
Franz B. Thiebaut,t Randolph D. Christen,* and Stephen B. Howellt
*Department ofGynecologic Oncology, Jikei University School ofMedicine, Tokyo, Japan; tSchool ofMedicine and the Cancer Center
and *Department ofSurgical Oncology, University ofCalifornia San Diego, La Jolla, California 92093;
and IDepartment ofPharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755
Abstract
A twofold change in the cisplatin (DDP) sensitivity of 2008
human ovarian carcinoma cells is sufficient to reduce tumor
response in vivo. The DDP sensitivity of these cells can be
enhanced by activation of the epidermal growth factor and pro-
tein kinase C signal transduction pathways. We report here
that two endogenous growth factors, bombesin and tumor ne-
crosis factor alpha (TNFa), enhanced DDP sensitivity by fac-
tors of 1.7±0.1 (SD)-fold and 1.8±0.1 (SD)-fold, respectively.
Both agents also produced sensitization in an 1 1-fold DDP-re-
sistant 2008 subline. Neither bombesin nor TNFa changed the
accumulation of DDP, glutathione content, or glutathione-S-
transferase activity in 2008 cells. However, a 2-h exposure to
both bombesin and TNFa was sufficient to increase 2008 clon-
ing efficiency by up to 2.6±0.1 (SD)-fold and 2.2±0.1 (SD)-
fold, and it increased average colony size by 1.35±0.1 (SD)-
fold and 1.55±0.1 (SD)-fold, respectively. Bombesin increased
intracellular free calcium, and this was blocked by the bombe-
sin receptor-specific antagonist SC196, demonstrating that
2008 cells have functional bombesin receptors. These results
indicate that bombesin and TNFa can enhance sensitivity to
DDP in both DDP sensitive and resistant variants of a human
ovarian carcinoma and that both agents serve as growth factors
for this tumor. (J. Clin. Invest. 1992. 90:1436-1442.) Key
words: drug resistance* signal transduction pathway * intracel-
lular calcium * chemotherapy * mitogenesis * growth factor
Introduction
Ligand binding to a variety ofreceptors triggers the rapid gener-
ation of inositol triphosphate and diacylglycerol leading to the
activation of protein kinase C (PKC)1 ( 1 ). Bombesin, a tetra-
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1. Abbreviations used in this paper: (Ca2 )i, intracellular free calcium;
DDP, cis-diamminedichloroplatinum(II); [3H]DEP, cis-dichloro-
([3H]-ethylenediamine)-platinum(II); EGF, epidermal growth fac-
tor; GST, glutathione-S-transferase; mCB, monochlorobimane; PKC,
protein kinase C; TNFa, tumor necrosis factor-alpha; TPA, 12-O-te-
tradecanoylphorbol- I 3-acetate.
decapeptide originally isolated from frog skin (2), has been
shown to act as a mitogen for Swiss 3T3 fibroblasts (3) and
human small cell lung carcinomas (4). This peptide also has
potent pharmacological effects on pancreatic cells (5) and
elicits the release of other peptide hormones such as insulin.
Since the administration ofthis hormone stimulates the release
of other peptides, it is difficult to obtain evidence for a direct
biological activity ofbombesin. In Swiss 3T3 cells, high affinity
receptors specific for this peptide have been demonstrated (6),
and bombesin is able to directly activate PKC (7). There is also
indirect evidence that bombesin can activate PKC in human
tumor cells based on its ability to generate inositol triphos-
phates and increase intracellular free calcium [(Ca2+)i] (5, 8).
Tumor necrosis factor-a (TNFa), secreted by macro-
phages (9), is a cytokine with a wide range ofregulatory actions
on immune responses, inflammation, cell growth, and differ-
entiation (10). TNFa has been reported to enhance the cyto-
toxicity of cis-diamminedichloro-platinum(II) (DDP) in vitro
to a human stomach adenocarcinoma ( 1) and a human ovar-
ian carcinoma cell line ( 12 ). In contrast, TNFa does not dem-
onstrate an actual synergistic effect when combined with DDP
in a human bladder transitional cell carcinoma in vivo ( 13).
Furthermore, when TNFa was administered for the treatment
of intraperitoneal ovarian cancer xenografts, although it pro-
longed survival in tumor-bearing mice (10), it also promoted
the establishment of multiple subperitoneal tumors. Like 12-
O-tetradecanoyl-phorbol-l 3-acetate (TPA), TNFa activates
PKC in some cell types and this in turn may result in increased
AP-l activity and induction of AP-l-responsive genes ( 14).
This is considered to be a key mechanism mediating at least
some of the biological effects ofTNFa mentioned above.
We have previously reported that TPA activation of PKC
increased DDP sensitivity by a factor of 2.5-fold in human
ovarian carcinoma 2008 cells ( 15). Likewise, epidermal
growth factor (EGF), another potent activator of PKC, en-
hances DDP sensitivity by 3.1-fold in the same cell line ( 16).
We report here that bombesin and TNFa, two endogenous
ligands whose receptors have the potential of activating PKC,
are also potent modulators of DDP sensitivity in 2008 cells
and, moreover, are both mitogenic for this tumor.
Methods
Materials. Bombesin was purchased from Sigma Chemical Co. (St.
Louis, MO). TNFa was purchased from Sigma Chemical Co. and
Knoll Pharmaceuticals (Whippany, NJ). DDP was obtained from the
Drug Synthesis and Chemistry Branch, Division ofCancer Treatment,
National Cancer Institute (Bethesda, MD). Monochlorobimane
(mCB) was purchased from Molecular Probes, Inc. (Eugene, OR). A
stock solution ofmCB was prepared in ethanol (20 mM) and was kept
at 0-5°C, protected from light. cis-Dichloro([3H]-ethylenediamine)-
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platinum(II) ([3H]DEP) (specific activity . 16.4 (mCi/mmol), an
analog of DDP that produces adducts at identical sites in DNA, was
synthesized as previously reported ( 17 ).
Tumor cell lines. The human cell line 2008 was established from a
patient with a serious cystadenocarcinoma of the ovary ( 18 ). A resis-
tant subline, designated 2008/C13*5, was obtained by 13 monthly
selections with 1 MM DDP followed by chronic exposure to DDP in-
creased stepwise to 5 MM ( 19). The cells were grown on tissue culture
dishes in a humidified incubator at 370C in a 5% CO2 atmosphere.
They were maintained in medium consisting of RPMI 1640 supple-
mented with 5% heat inactivated fetal calf serum, 2 mM glutamine,
100 U/ml penicillin, and 100 Ag/ml streptomycin (Irvine Scientific,
Santa Ana, CA).
Bombesin and TNFa treatment and colony assays. Colony-form-
ing assays were used to assess the mitogenic and sensitization effects of
each factor (20). Cells, trypsinized from monolayer culture, were ad-
justed to a concentration of 3,750 cells/5 ml in a tissue culture tube
(Corning Glass Works, Corning Medical and Scientific, Corning, NY).
5 Ml of bombesin or TNFa stock solution was added to each tube to
produce a final concentration of 300 or 2.4 nM, respectively. 10 Jl of
DDP diluted from the stock solution was then added; control tubes
received diluent alone. Tubes were incubated in humidified 5% CO2 in
air for 2 h. Each tube was then centrifuged and the cells were resus-
pended in 15 ml of complete medium devoid of drugs, and 5 ml of
suspended cells were plated on 60-mm polystyrene tissue culture dishes
(Corning Glass Works) in triplicate. Plates were incubated in humidi-
fied 5% CO2 air, and after 14 d plates were fixed with methanol and
stained with Giemsa. Colonies of> 60 cells were counted macroscopi-
cally. For the measurement ofcolony size, the longest diameter ofeach
colony was determined microscopically in 50 colonies. Cloning effi-
cacy under control conditions was 8%.
Cell growth rate. Cell suspensions were incubated in tissue culture
tubes with either 300 nM bombesin or 2.4 nM TNFa for 2 h in humidi-
fied 5% CO2 in air. Each tube was then centrifuged and the resuspended
cells were seeded at low density in the absence ofbombesin orTNFa (2
X 104/well) in 24-well plates (Corning Glass Works). Cells were har-
vested at various time points and counted by hemocytometer.
[3H]DEP accumulation. Subconfluent monolayers of 2008 cells
were treated with 37°C RPMI 1640 medium containing 5 uCi/ml
[3H ]DEP and 5 MM cold DEP for 2 h. The medium was then aspirated,
and the cells were washed rapidly with 4°C PBS four times. 1 ml of 1 N
NaOH was added and the cells were allowed to digest overnight. A
25-Ml aliquot was used for determination of protein content by the
method of Bradford (21); 800 Ml was used for liquid-scintillation
counting.
GSH content and glutathione-S-transferase (GST) activity. GSH
content was measured by adjusting cells to 106/ml and staining them
with 25 MM mCB in complete medium at room temperature for the
indicated time; relative cellular fluorescence was then immediately
measured on a flow cytometer (Cytofluorograph lIs; Ortho Diagnostic
Systems Inc., Raritan, NJ) with excitation and emission settings of385
and 480 nm, respectively. Values were converted from log fluorescence
to linear fluorescence intensity by application of the equation x
= 1 0[(Y-20)/W6 where x is the relative linear fluorescent intensity and y is
the mean log channel number. Cells that were nonviable on the basis of
forward and right-angle light scatter were excluded from analysis. The
forward rate constant for the conjugation ofmCB by GST is given by
the equation Kf = initial rate/[mCB] [GSH]. Since the GSH content
in the unstimulated and stimulated state turned out to be the same, and
the mCB concentration was identical, the effects of bombesin and
TNFa induction on Kf could be estimated from their effects on the
initial slope of the conjugation curve.
DNA adduct formation. Confluent monolayers growing in com-
plete RPMI in 150 cm2 culture flasks (Corning Glass Works) under-
went a medium change and were then incubated at 370C for 2 h with
10 MCi/ml [3H]DEP concurrently with either 300 nM bombesin or 2.4
nM TNFa. Cells were harvested by trypsinization, washed twice with
ice-cold PBS, and then resuspended in 0.8 ml of 100mM NaCl, 10mM
Tris-Cl, pH 8.0; 25 mM EDTA; 0.5% SDS; 0.1 mg/ml proteinase K,
and digested at 50'C for 18 h with shaking. This was followed by ex-
traction with phenol/chloroform, and the DNA was redissolved in 10
mM Tris-Cl pH 8.0, 1 mM EDTA containing 0.1 mg/ml RNase A and
digested at 370C for 3 h. After another extraction with phenol/chloro-
form, the DNA was precipitated with 70% ethanol and stored at
-70'C. The platinated DNA was digested to deoxyribonucleosides and
specific DNA-bound adducts were separated by HPLC (22). The peak
height of deoxycytosine measured at 254 nm during elution was con-
verted to nanomoles by comparison with a standard curve. The level of
DNA platination was then expressed as dpm associated with the intra-
strand guanine-guanine adduct/nmol deoxycytosine.
Cell cycle phase distribution. 1 x 106 log phase cells were exposed to
bombesin or TNFa for 2 h while growing as a monolayer, after which
the medium was replaced. Cells were harvested by trypsinization at 24,
48, and 72 h after exposure, fixed with ice-cold 70% ethanol, and then
resuspended at 106 cells/ml in PBS containing 50 MM propidium io-
dide and 1,000 U/ml RNase A and incubated for 30 min at 370 before
being analyzed on a flow cytometer(CytoFluorograph; Ortho Diagnos-
tics Systems, Inc.). The fraction of cells in each phase was determined
using Multicycle Cell Cycle Software (Phoenix Flow Systems, San
Diego, CA).
(Ca2"), release. Cells were loaded over 30 min with 5 MM of the
fluorescent (Ca2+)i probe FURA2/AM (Calbiochem, San Diego, CA)
in NaCl Ringer's solution maintained at 37°C and pH 7.4 by aeration
using a 95% 02 5% CO2 gas mixture. Loaded cells were then placed
onto a glass coverslip that had previously been coated with 5 mg/ml
poly-L-lysine (Sigma Chemical Co.). The coverslip was then briefly
rinsed in NaCl, removing any remaining extracellular dye but leaving a
number of cells attached to the poly-L-lysine coating, and then was
attached with high vacuum grease to a donut-shaped glass tube, creat-
ing a chamber in which the cell-coated coverslip served as the floor.
The glass-tubing wall of the chamber circulated heated water, and thus
the NaCl added to the chamber to bathe the cells, again aerated to pH
7.4, was maintained at 37°C. This chamber was placed on an inverted
microscope (Nikon Diaphot; Nikon Corp., Melville, NY), which was
fiberoptically connected to a spectrofluorometer (SPEX AR-CM
DM3000; SPEX Industries Inc., Edison, NJ). For each experiment, a
small group (5-10) of loaded cells was selected and alternately excited
at 340 nm and 380 nm while fluorescent emissions were measured at
505 nm. Initially, emissions were measured while the cells were being
bathed in NaCl. After 60-120 s, 300 nM bombesin was added to the
bath and scanning continued. Approximately 2 min later, 25 MM ofthe
calcium ionophore ionomycin (Sigma Chemical Co.) was added to the
solution, followed in - 60 s by the addition of 60-120 mM of the
calcium-chelating agent, EGTA (Sigma Chemical Co.). These last two
additions were necessary for calibration ofthe FURA dye emissions to
calculate (Ca2+)i levels using the Grynkiewicz Equation (23). Emis-
sion intensities from 2008 cells that were not loaded with the fluores-
cent probe were similarly recorded, and these measured "autofluores-
cent" emissions were subtracted from measured intensities emitted by
the loaded cells before calculating (Ca2+)i concentrations.
In a second set of experiments, identically loaded 2008 cells were
exposed for 15 min to 30 MM SC196, Ac-Met-Tyr-Pro-Arg-Gly-Asn-
His-Trp-Ala-Val-Gly-His-LeufLeu-NH2 (a generous gift of Drs. John
Steward and Lajos Gere, UCHSC, Denver, CO), a highly specific bom-
besin-receptor antagonist (24), before excitation. Initially, cells were
excited while being bathed in NaCl plus 30 MM SC 196. Bombesin 300
nM was added to the physiologic solution after 2 min. The ratio of
340:380 nm emission intensities was calculated to determine whether
changes in (Ca2+)i concentrations occurred in response to the addition
of bombesin.
Results
Effect ofbombesin and TNFa on DDP sensitivity. Fig. I (left)
shows that when 2008 cells were exposed concurrently for 2 h
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Figure 1. Sensitivity of2008 cells to DDP in the presence (closed cir-
cles) or absence (open circles) of growth factors. Cells were treated as
follows: (left) 2,!h exposure to DDP concurrently with 300 nM born-
besin; (right) 2 h exposure to DDP concurrently with 2.4 nM TNFa.
DDP cytotoxicity was determined by clonogenic assay. Data points
represent mean values of three experiments performed with triplicate
cultures; bars represent SD.
to 300 nM bombesin and DDP, and then both agents were
removed from the cultures during the period of colony forma-
tion, bombesin increased DDP sensitivity. The IC50 in the ab-
sence ofbombesin was 4.50±1.0 ,uM (SD), whereas in the pres-
ence ofbombesin it was 2.67±0.21 jM (SD). Thus, bombesin
produced a 1.7-fold increase in sensitivity (n = 3; P < 0.01).
Likewise, the Fig. 1 (right) shows that when 2008 cells were
exposed concurrently for 2 h to 2.4 nM TNFa and DDP,
TNFa increased DDP sensitivity. The IC50 in the presence of
TNFa was 2.57±0.29 ,uM (SD). Thus, TNFa produced a 1.8-
fold increase in sensitivity (n = 3; P < 0.01). Both bombesin
and TNFa at concentrations even up to 10 and 120 ,uM did not
cause any toxicity by themselves; thus, the interaction between
bombesin and TNFa and DDP was truly synergistic as defined
by median effect analysis (25).
Enhancement of sensitivity in DDP-resistant cells. The
2008/C13*5 cell line is 11-fold resistant to DDP. Fig. 2 (left)
shows that when these cells were exposed for 2 h concurrently
to bombesin and DDP, the IC50 was reduced from 39.0 to 21.5
,uM. The 1.6±0.3 (SD)-fold sensitization, quantitated by
change in the slope of linear portion of these dose-response
curves, was nearly identical to the 1.7-fold sensitization ob-
served in the DDP-sensitive 2008 cells (n = 3; P < 0.01 ). Simi-
larly, Fig. 2 (right) shows that when cells were exposed for 2 h
concurrently to TNFa and DDP, the IC50 was reduced to 22.5
,M. The 1.6±0.9 (SD)-fold sensitization, quantitated by
change in the slope of these curves, was likewise nearly identi-
cal to the 1.8-fold sensitization observed in the DDP-sensitive
2008 cells (n = 3; P < 0.01). Thus we concluded that both
bombesin and TNFa increased DDP sensitivity as effectively
in DDP-resistant as in DDP-sensitive variants of 2008.
Effect ofbombesin and TNFa on cellular accumulation of
[3H]DEP. The 2008 cells were treated concurrently with
[3H]DEP and either bombesin or TNFa for 2 h. A vehicle
control consisting of an appropriate dilution of saline was run
concurrently. Neither the bombesin nor the TNFa produced
any effect on cellular accumulation of [3H ] DEP. Cells treated
with saline contained 41.1±0.3 (SD) pmol/mg protein,
whereas those treated with the bombesin contained 38.4±2.2
(SD) pmol/mg protein and those treated with TNFa con-
tained 38.5±0.1 (SD) pmol/mg protein. Thus, bombesin and
TNFa altered DDP sensitivity by a mechanism that does not
involve an increased amount of drug entering the cell.
Effect ofbombesin and TNFa on cellular GSH content and
the activity of GST. mCB reacts quantitatively with GSH via
GST to form a fluorescent product readily quantitated by flow
cytometry. 2008 cells were stained with 25 gM mCB for
various periods of time and relative fluorescence was deter-
mined immediately by flow cytometry. Maximum staining was
obtained by 50 min,and this staining time was used for compar-
ison of GSH content. GSH content of bombesin-treated cells
was 103±10% (SD; n = 3) of that in the untreated cells; the
relative GSH content ofTNFa-treated cells was 96.5±2% (SD;
n = 3). Thus, bombesin and TNFa did not alter GSH content
significantly. Since there was no difference in GSH content, the
initial rate of reaction between GSH and mCB can be used to
estimate the rate constant for the GST-mediated reaction of
mCB with GSH, assuming that mCB has equal access to the
GSH in both cell types. GST activity in the presence ofbombe-
sin was 96.7±8.3% (SD) of that in the untreated cells; in the
case of TNFa it was 103.6±8.9% (SD). Thus, bombesin and
TNFa did not produce a significant change in GST when activ-
ity was assayed in this manner.
Effect of bombesin and TNFa on platinum DNA adduct
formation. Intrastrand DNA cross-link formation can be quan-
titated using [3H ]DEP as reported by Eastman ( 17 ). This tech-
nique specifically permits quantitation of the most abundant
adduct, the guanine-guanine intrastrand cross-link. [3H]DEP
DNA adduct formation in bombesin or TNFa-treated 2008
cells was 110.7±27.47 (SD) and 128.33±15.14 (SD) dpm/
nmol deoxycytosine, whereas it was 108.7±6.03 (SD) in un-
treated control cells. Thus, despite increasing DDP sensitivity,
bombesin and TNFa did not cause any significant increase in
DNA intrastrand cross-link formation.
Dose-dependent effect ofbombesin and TNFa on clonogeni-
city of2008 cells. Fig. 3 shows the effect of a 2-h exposure to
bombesin (top) and TNFa (bottom) on the subsequent cloning
efficiency of 2008 cells. Bombesin increased the cloning effi-
lu I
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Figure 2. The effect ofbombesin and TNFa on the DDP sensitivity of
DDP-resistant cells. Cl 3*5 cells were treated with various concentra-
tions ofDDP in the presence (closed circles) or absence (open circles)
of 300 nM bombesin (left) or 2.4 nM TNFa (right) for 2 h. DDP
cytotoxicity was determined by clonogenic assay on plastic dishes.
Data points are mean values of three experiments performed with
triplicate cultures; bars represent SD.
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Figure 3. Dose-depen-
dent effect of bombesin
and TNFa on 2008
cloning efficiency. Cells
were treated as follows:
(top) 2-h drug exposure
to bombesin at various
concentrations from 10
nM to 10 MM; (bottom)
2-h drug exposure to
TNFa at various con-
centrations from 0.12
to 120 nM. Data points
represent the mean of
two experiments per-
formed with triplicate
cultures; bars represent
SD (where greater than
symbol size).
cacy in a dose-dependent fashion with the maximum of
262±6% (SD) of control being attained at a concentration of4
,uM (n = 2; P < 0.01 ). Similarly, TNFa increased clonogenicity
in a dose-dependent fashion, producing a maximum of
221±11% (SD) relative to control at a concentration of 12 nM
(n = 2; P < 0.01), after which a plateau was observed. Thus
both bombesin and TNFa enhanced the cloning efficacy of
2008 cells with the maximum effect ofbombesin being greater
than that of TNFa.
Effect ofbombesin and TNFa on colony-size distribution.
Fig. 4 shows the colony-size distribution of control 2008 cells
(top) or 2008 cells treated with either 300 nM bombesin (mid-
dle) or 2.4 nM TNFa (bottom) for 2 h and then washed before
plating. In this experiment cells were cultured for 15 d after
treatment with bombesin or TNFa to obtain larger colonies.
Both bombesin and TNFa shifted the frequency histogram to
the right. The average colony diameter in the control case was
15 -
Control
10
5
Bombesin
10 300 nM
15I> .iIiI.....
10
TNF-a
5jj-jtjj_
Colony Size, mm
Figure 4. Colony-size
distribution in the pres-
ence or absence of
growth factors. Cells
were treated as follows:
(top) cells were cultured
without any factors;
(middle) 2-h drug expo-
sure to 300 nM bombe-
sin alone; (bottom) 2-h
drug exposure to 2.4
nM TNFa alone. Col-
ony diameter was deter-
mined by a microscope
fitted with a microme-
ter.
1.20±0.26 mm (SD), whereas after treatment with bombesin it
was 1.70±0.40 mm (SD), an increase of 1.42-fold (n = 45; P
< 0.01 ). Similarly, the mean colony size after treatment with
TNFa was 2.01±0.55 mm (SD), an increase of 1.68-fold (n
-45;P<0.01).
It should be noted that both bombesin and TNFa increased
the range of colony sizes. For the control cultures size ranged
from 0.6 to 1.7 mm, whereas it ranged from 1.0 to 2.85 mm
after exposure to bombesin and from 1.3 to 4.0mm after expo-
sure to TNFa. Thus the coefficient of variation in colony size
after treatment with either bombesin or TNFa was larger than
control.
Dose dependence of the effect of bombesin and TNFa on
colony size. Table I shows that, like the effect on cloning effi-
ciency, the effect ofbombesin and TNFa on mean colony size
was also concentration dependent. Despite the small size ofthe
colonies in these experiments (cells were incubated for 10 d
after drug treatment) compared with the data presented above,
bombesin significantly increased the colony size at each dose
level (n = 20; P < 0.01), and the maximum colony size was
observed at a bombesin concentration of 400 nM. Similarly,
TNFa significantly increased the colony size in each dose level
(n = 20; P < 0.01), and the maximum colony size was ob-
served at a TNFa concentration of 4.0 nM. The maximum
increase in mean colony size with bombesin was 1.36±0.07
(SD)-fold, whereas it was somewhat larger at 2.04±0.10 (SD)-
fold with TNFa (n = 20; P < 0.01 ).
Effect ofbombesin and TNFa on growth rate of2008 cells.
An increase in apparent cloning efficiency and mean colony
size is most readily explained by an increase in cell-doubling
rate. Bombesin 300 nM and TNFa 2.4 nM increased the expo-
nential growth-rate constant of 2008 cells by a factor of
1.09±0.01 (SD) and 1.15±0.01 (SD), (P< 0.01, ttest), respec-
tively. Although bombesin and TNFa had equivalent mito-
genic effects on 2008 cells with regard to growth rate at the
concentrations used, neither agent altered the level of the
plateau phase of growth (data not shown).
A further demonstration ofthe mitogenic effect ofbombe-
sin and TNFa is shown in Fig. 5. Cells were treated with a
single 2-h exposure to 300 nM bombesin or 2.4 nM TNFa,
Table I. Effect ofBombesin and
Tumor Necrosis Factor-a on Average Colony Size
Growth Fold
factor Concentration Colony size* increase*
nM MM
Bombesin 0 0.76±0.05 1.00
100 0.84±0.04* 1.10±0.06
400 1.04±0.05* 1.36±0.07
4000 0.90±0.05* 1.18±0.07
TNFa 0 0.76±0.05 1.00
0.4 1.01±0.06* 1.32±0.07
4.0 1.55±0.08* 2.04±0.10
40.0 1.55±0.04*§ 2.03±0.05
* Mean±SD.
* P < 0.01 relative to control.
I P < 0.01 relative to 400 mM bombesin.
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washed, and the cell cycle phase distribution determined by
flow cytometry at 24-h intervals for 3 d. Both agents produced
an increase in the fraction of cells in S phase at the expense of
GI phase by 24 h (P < 0.05 for both). After exposure to TNFa
this cell-cycle phase perturbation returned to normal by 48 h;
the response was more prolonged with bombesin, requiring 72
h to return to baseline. Control cells, which were plated at the
same density as bombesin- and TNFa-treated cells, showed no
perturbation ofthe cell cycle phase distribution during the 72-h
observation period. This indicates that during the experiment
the cells remained in log phase growth. These results indicate
that the effect of a 2-h exposure to bombesin and TNFa on
cloning efficiency and colony size can be accounted for by a
direct mitogenic effect on cell proliferation.
(Ca2+)i release. To demonstrate the presence of functional
bombesin-specific receptors on 2008 cells, the effect ofbombe-
sin on (Ca2+ )i was measured in the presence and absence ofthe
bombesin-specific antagonist SCl 96. When grown in 5% bo-
vine calf serum, 300 nM bombesin increased (Ca2+)i in 8% of
the cells, whereas when grown in 5% fetal calf serum, or when
serum starved for 24 h, bombesin increased (Ca2+)i in 50 and
100% of 2008 cells, respectively. In cells grown in fetal calf
serum and then serum starved for 24 h, the basal (Ca2+)i varied
between 63 and 284 nM. Bombesin increased (Ca2+)i concen-
tration by 1.13- 1.68-fold in 100% of60 cells examined. A typi-
cal example of this response to 300 nM bombesin is shown in
Fig. 6, which also shows that the bombesin-specific antagonist
SC196 completely blocked the ability of 300 nM to elevate
(Ca2+). This blockade was observed in 100% of the 60 cells
examined.
Effect ofcell density on DDP sensitivity. Fig. 7 shows that
there is no difference between cells grown in different densities
with respect to DDP sensitivity. In both cases ICse for 1 h of
DDP exposure was 1.5 MM. It is obvious that the confluency of
:0
U)
Sa.1
Figure 6. The effect of
cell density on the DDP
sensitivity of2008 cells.
Cells were treated 1 h
with various concentra-
o t tions of DDP in cell
suspension from half-
confluent (open circle)
and over-confluent
(closed circle) parent
cultures. DDP cytotox-
icity was determined by
clonogenic assay on
plastic dishes. Data
points are mean values
of three experiments
performed with tripli-
0 2 4 6 8 cate cultures; bars repre-
DDP Concentration, uM sent SD.
the starting parent culture has no effect on final DDP cell sur-
vival.
Discussion
The finding that bombesin induces activation ofPKC (7) and
the wide distribution of endogenous mammalian analogs of
bombesin (26) suggest that this peptide may play an important
role in controlling the phenotype of both normal and malig-
nant cells. Such a role has already been established for TNFa,
which is also capable ofactivating PKC in some cell types (14).
The first major finding resulting from the studies reported
here was that the signal transduction pathways activated by
both bombesin and TNFa can modulate the sensitivity of the
human ovarian carcinoma cell line 2008 to DDP, the most
clinically important drug for the treatment ofthis malignancy.
The effect was produced by exposure to growth factor forjust 2
h, indicating that enhancement of sensitivity was the result of
the triggering of a cascade ofevents initiated by ligand binding
rather than a mechanism that required the continuous pres-
ence of exogenous ligand. Other investigators have also found
that TNFa will modulate DDP sensitivity in a human ovarian
carcinoma (12) and a gastric adenocarcinoma (11) cell line,
but the ability ofbombesin to enhance sensitivity to DDP has
not been reported previously. Bombesin and TNFa thus join a
rapidly growing list of receptor ligands and other signal trans-
duction pathway activators that modulate DDP sensitivity in
2008 cells. We have previously reported that brief exposure to
EGF (16), activation of the PKC pathway with TPA (15), or
activation of the protein kinase A pathway with forskolin (27)
all enhance DDP sensitivity to varying degrees. Although the
magnitude of the modulation produced by all of these activa-
tors is relatively small (1.6-3.2-fold), levels of resistance as
small as 2.5-fold produce clearly reduced response to DDP
treatment in vivo when the 2008 cells are grown as a xenograft
(28). Irrespective ofwhether such modulation is clinically rele-
vant, the ability of these factors to enhance sensitivity in the
2008 cells provides an additional approach to understanding
the mechanism by which cells defend themselves against this
chemotherapeutic agent.
The major mechanisms mediating resistance to DDP in-
clude impairment of drug uptake, elevated levels of GSH or
metallothioneins, or enhanced DNA repair (for review see ref-
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Figure 7. Elevation of (Ca2+)i in response to bombesin. A typical ex-
ample of the effect ofbombesin on (Ca2+)i concentration are shown.
Measurements were done in the absence (top) and in the presence
(bottom) of 30 AM bombesin-specific antagonist SC 196.
erence 29). The mechanism by which signal transduction acti-
vators modulate DDP sensitivity appears to vary. In the case of
activation of the protein kinase A pathway, the major effect is
an increase in DDP uptake (27), whereas activation of the
EGF receptor or PKC does not alter uptake (15, 16). Bombe-
sin and TNFa were selected for study because they are possible
endogenous activators ofPKC (9, 26). Like TPA they failed to
enhance DDP uptake, produced no change in GSH content or
apparent GST activity, and did not alter the number of intra-
strand cross-links formed. It is unlikely that enhancement of
DDP sensitivity is mediated by a decrease in metallothioneins
since these are relatively stable proteins with cellular half-lives
of many hours (15) whereas the sensitization response was
observed by 2 h. No information is yet available on the effect of
either TPA or bombesin and TNFa on the ability of 2008 cells
to remove DDP adducts from DNA, and the mechanism ofthe
bombesin and TNFa effect on DDP sensitivity remains to be
determined. It is also noteworthy that, like TPA (15) but un-
like EGF (16), bombesin and TNFa were able to modulate
DDP sensitivity in both the DDP-sensitive and -resistant vari-
ants of 2008. In the case of EGF, we have been able to show
that ability to modulate DDP sensitivity is a function of both
EGF concentration and receptor number ( 16). However, sensi-
tivity to bombesin and TNFa is largely determined at the post-
receptor level (6, 7, 30), and such a relationship may not per-
tain to either of these factors.
The second major finding to emerge from these studies was
that both bombesin and TNFa are mitogenic for human ovar-
ian carcinoma 2008 cells. Although TNFa is cytotoxic to many
types of tumors in vitro and in vivo, against 2008 cells it pro-
duced an effect similar to that ofbombesin in stimulating clon-
ing efficiency, colony size, and growth rate. Although the num-
ber of cell-surface receptors for bombesin and TNFa were not
determined, these data clearly indicate the existence of physio-
logically significant numbers of receptor types responsive to
both factors.
A direct mitogenic effect of bombesin has been reported for
several other cells types, including small cell carcinomas (4)
and Swiss 3T3 fibroblasts. Swiss 3T3 cells exhibit large num-
bers of receptors for a variety ofgrowth factors, including bom-
besin (31), and a mitogenic effect was observed using a bombe-
sin concentration only 3% of that needed by the 2008 cells. A
mitogenic response to TNFa was reported also for human as-
trocytoma cells (32); although receptor number was not quan-
titated, the concentration of TNFa at which the effect was ob-
served was well within the concentration range needed to pro-
duce a response in 2008 cells.
It is of interest that the mitogenic effect of bombesin and
TNFa was very prolonged. A 2-h exposure to either agent fol-
lowed by washing of the cells was sufficient to commit the 2008
cells to a change in growth rate that was still apparent 24-48 h
later, and a change in the size of colonies produced that was
detectable 15 d later. We have reported this same sort of re-
sponse with EGF, where a brief exposure was sufficient to com-
mit the 2008 cells to an altered colony morphology that was
still present 10-14 d later (16). We speculate that the effects of
bombesin and TNFa on the growth of 2008 cells may be indi-
rect, and that brief exposure to either may be initiating the
production of an autocrine growth factor that either produces
and maintains the alteration in cytokinetics or potentiates such
effects of factors already present in the culture medium. It is
important to emphasize that the ability ofbombesin and TNFa
to enhance DDP sensitivity may not be linked to their mito-
genic effects; these may be entirely independent effects of re-
ceptor activation.
The concentration of bombesin causing mitogenesis in
2008 cells was substantially higher (maximum effect 4,000
nM) than that required for mitogenesis in Swiss 3T3 (33) or
human small cell lung carcinoma lines (34) cells, raising the
question of whether bombesin was working via another recep-
tor. However, the studies with Swiss 3T3 and nonsmall cell
lung cancer cells lines used continuous exposure to bombesin
or gastrin-releasing peptide, whereas the dose-response curve
depicted in Fig. 3 was obtained using only a 2-h exposure.
Moreover, the ability of the bombesin receptor-specific inhibi-
tor SC 196 to block the bombesin-induced increase in (Ca2+ )
established that the 2008 cells do contain bona fide bombesin
receptors but not that this receptor type is responsible for the
mitogenic or sensitizing response. These cells may also contain
neuromedian B receptors, and it is possible that both receptor
types may contribute to the mitogenic or sensitizing responses
or that bombesin is producing these responses indirectly via
another growth factor that is less effective on 2008 than the
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other cell types. Because ofthe toxicity ofSC 196 to 2008 cells it
has not been possible to establish that blockade of the bombe-
sin receptors can inhibit the bombesin-induced increase in
DDP sensitivity or proliferation rate.
Interest in TNFa as a potential regulator ofDDP sensitivity
and/or tumor growth in human ovarian carcinoma is height-
ened by reports that a significant fraction of these tumors ap-
pear to produce TNF (35) and that TNF treatment of several
human ovarian carcinoma xenografts increases their local inva-
siveness ( 10). TNFa is currently being tested in the United
States as a treatment for ovarian carcinoma. Both our results
and those of other investigators ( 10, 35, 36) suggest the need
for caution and careful assessment of whether TNFa might be
detrimental to such patients.
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